Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. (Q30383418)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

21 June 2017

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. (English)

1 reference

Europe PubMed Central

21 June 2017

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Gregory M Glenn

1

1 reference

Europe PubMed Central

21 June 2017

D Nigel Thomas

2

1 reference

Europe PubMed Central

21 June 2017

Kimber L Poffenberger

3

1 reference

Europe PubMed Central

21 June 2017

David C Flyer

4

1 reference

Europe PubMed Central

21 June 2017

Larry R Ellingsworth

5

1 reference

Europe PubMed Central

21 June 2017

Bo H Andersen

6

1 reference

Europe PubMed Central

21 June 2017

Sarah A Frech

7

1 reference

Europe PubMed Central

21 June 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

27 Suppl 6

1 reference

Europe PubMed Central

21 June 2017

G60-6

1 reference

Europe PubMed Central

21 June 2017

Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Influenza vaccine supply: building long-term sustainability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Current status and progress of prepandemic and pandemic influenza vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Emulsion-based adjuvants for influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Vaccines for seasonal and pandemic influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Prioritization of pandemic influenza vaccine: rationale and strategy for decision making.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Response to a monovalent 2009 influenza A (H1N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Correlated Studies of a Recombinant Influenza-Virus Vaccine. III. Protection against Experimental Influenza in Man

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Efficacy of Purified Influenza Subunit Vaccines and Relation to the Major Antigenic Determinants on the Hemagglutinin Molecule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Protection of infants from infection with influenza A virus by transplacentally acquired antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.10.031

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30383418&oldid=1984424044"